IBJNews

Analysts: Investors wrong to dump Endocyte

Back to TopCommentsE-mailPrintBookmark and Share

Investors on Friday dumped shares of West Lafayette-based Endocyte Inc. after an independent analysis said an experimental lung cancer drug is unlikely to be declared superior to existing chemotherapy. But two analysts say, to the contrary, the analysis shows the prospects for Endocyte’s drug are as good as ever.

Endocyte is studying the drug vintafolide in patients with non-small-cell lung cancer and comparing its effects to an existing chemotherapy drug called docetaxel.

Vintafolide has already shown strong effects against late-stage ovarian cancer, and Endocyte has moved to win regulators’ approval for that disease in Europe. But Endocyte also thinks vintafolide could work against other types of cancer, such as lung and breast.

What Endocyte reported Friday were the results of a mid-stage analysis of a clinical trial by the Data Safety Monitoring Board. The board conducted a futility analysis of vintafolide and found that it’s at least good enough for doctors to continue giving it to patients.

What the board also found was that it is unlikely that vintafolide alone will show itself superior to docetaxel at extending the progression-free survival times of lung cancer patients. But as Wall Street analysts pointed out, the trial has enough patients to show superiority only if vintafolide extends patients’ progression-free survival 50 percent longer than Doxil.

“We are surprised at the stock’s negative reaction,” wrote Wedbush Securities analyst Gregory White in a Friday note to investors. Endocyte shares fell more than 14 percent on Friday and have fallen even more on Monday to below $10 per share—their lowest level since March.

Vintafolide could still prove superior to docetaxel, and yet not be able to show that superioty in this particular clinical trial. It’s also possible that vintafolide could end up being inferior to Doxil, wrote RBC Capital Markets analyst Adnan Butt in a Friday note to investors.

The same goes for another part of Endocyte’s study, which compares a combined dose of both vintafolide and docetaxel against docetaxel alone. Docetaxel was once sold under the brand name Taxotere.

“For either the combination [dose] arm or the single agent vintafolide arm to show superiority over docetaxel was a high bar especially at the interim” point in the clinical trial,” Butt wrote.

Butt and White said the key positives from the analysis are that vintafolide is safe enough and at least close enough to docetaxel in effectiveness for the trial to keep going. And, they noted, the combination of vintafolide and docetaxel could still prove to be superior to docetaxel alone.

They both reiterated their positive recommendations on Endocyte’s stock.

For its part, Endocyte said it was encouraged by the board’s analysis of vintafolide.

"We are very pleased that our combination therapy of vintafolide and docetaxel successfully passed the pre-defined interim analysis, and we look forward to announcing the top-line results of this trial early next year," said Dr. Binh Nguyen, vice president of clinical development at Endocyte, in a prepared statement.

ADVERTISEMENT

Post a comment to this story

COMMENTS POLICY
We reserve the right to remove any post that we feel is obscene, profane, vulgar, racist, sexually explicit, abusive, or hateful.
 
You are legally responsible for what you post and your anonymity is not guaranteed.
 
Posts that insult, defame, threaten, harass or abuse other readers or people mentioned in IBJ editorial content are also subject to removal. Please respect the privacy of individuals and refrain from posting personal information.
 
No solicitations, spamming or advertisements are allowed. Readers may post links to other informational websites that are relevant to the topic at hand, but please do not link to objectionable material.
 
We may remove messages that are unrelated to the topic, encourage illegal activity, use all capital letters or are unreadable.
 

Messages that are flagged by readers as objectionable will be reviewed and may or may not be removed. Please do not flag a post simply because you disagree with it.

Sponsored by
ADVERTISEMENT

facebook - twitter on Facebook & Twitter

Follow on TwitterFollow IBJ on Facebook:
Follow on TwitterFollow IBJ's Tweets on these topics:
 
Subscribe to IBJ
  1. why oh why does this state continue to elect these people....do you wonder how much was graft out of the 3.8 billion?

  2. i too think this is a great idea. I think the vision and need is there as well. But also agree with Wendy that there may be better location in our city to fulfill this vision and help grow the sports of hockey and figure skating in Indy. Also to help further develop other parts of the city that seem often forgotten. Any of the other 6 townships out side of the three northernmost could benefit greatly from a facility and a vision like this. For a vision that sounds philanthropic, the location is appears more about the money. Would really like to see it elsewhere, but still wish the development the best of luck, as we can always use more ice in the city. As for the Ice growth when they return, if schedules can be coordinated with the Fuel, what could be better than to have high level hockey available to go see every weekend of the season? Good luck with the development and the return of the Ice.

  3. How many parking spaces do they have at Ironworks? Will residents have reserved spaces or will they have to troll for a space among the people that are there at Ruth Chris & Sangiovese?

  4. You do not get speeding ticket first time you speed and this is not first time Mr.Page has speed. One act should not define a man and this one act won't. He got off with a slap on the wrist. I agree with judge no person was injured by his actions. The state was robbed of money by paying too much rent for a building and that money could have been used for social services. The Page family maybe "generous" with their money but for most part all of it is dirty money that he obtained for sources that are not on the upright. Page is the kind of lawyer that gives lawyers a bad name. He paid off this judge like he has many other tine and walked away. Does he still have his license. I believe so. Hire him to get you confiscated drug money back. He will. It will cost you.

  5. I remain amazed at the level of expertise of the average Internet Television Executive. Obviously they have all the answers and know the business inside and out.

ADVERTISEMENT